KR20230142701A - 중증 급성 호흡기 증후군-관련 코로나바이러스를 표적화하는간섭 rna 및 covid-19 치료를 위한 그의 용도 - Google Patents

중증 급성 호흡기 증후군-관련 코로나바이러스를 표적화하는간섭 rna 및 covid-19 치료를 위한 그의 용도 Download PDF

Info

Publication number
KR20230142701A
KR20230142701A KR1020237022322A KR20237022322A KR20230142701A KR 20230142701 A KR20230142701 A KR 20230142701A KR 1020237022322 A KR1020237022322 A KR 1020237022322A KR 20237022322 A KR20237022322 A KR 20237022322A KR 20230142701 A KR20230142701 A KR 20230142701A
Authority
KR
South Korea
Prior art keywords
seq
sars
cov
sirna
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237022322A
Other languages
English (en)
Korean (ko)
Inventor
이충 창
치판 양
이펜 첸
치아춘 양
유안린 초우
Original Assignee
마이크로바이오 (상하이) 컴퍼니 리미티드
원니스 바이오테크 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마이크로바이오 (상하이) 컴퍼니 리미티드, 원니스 바이오테크 컴퍼니 리미티드 filed Critical 마이크로바이오 (상하이) 컴퍼니 리미티드
Publication of KR20230142701A publication Critical patent/KR20230142701A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237022322A 2020-12-03 2021-12-03 중증 급성 호흡기 증후군-관련 코로나바이러스를 표적화하는간섭 rna 및 covid-19 치료를 위한 그의 용도 Pending KR20230142701A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/133565 2020-12-03
CN2020133565 2020-12-03
CNPCT/CN2021/121762 2021-09-29
CN2021121762 2021-09-29
PCT/CN2021/135476 WO2022117085A1 (en) 2020-12-03 2021-12-03 Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19

Publications (1)

Publication Number Publication Date
KR20230142701A true KR20230142701A (ko) 2023-10-11

Family

ID=81853844

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022322A Pending KR20230142701A (ko) 2020-12-03 2021-12-03 중증 급성 호흡기 증후군-관련 코로나바이러스를 표적화하는간섭 rna 및 covid-19 치료를 위한 그의 용도

Country Status (8)

Country Link
US (1) US20240026362A1 (https=)
EP (1) EP4256055A4 (https=)
JP (1) JP2023553610A (https=)
KR (1) KR20230142701A (https=)
CN (1) CN116964202A (https=)
AU (1) AU2021390130A1 (https=)
IL (1) IL303367A (https=)
WO (1) WO2022117085A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117919267B (zh) * 2024-01-24 2024-12-03 石河子大学 miR2911在制备抗猪繁殖与呼吸障碍综合症病毒的药物中的应用
CN118001297B (zh) * 2024-02-01 2025-01-28 中国人民解放军军事科学院军事医学研究院 一种治疗SARS-CoV-2及其变体感染的多功能组合物及其制备方法
CN118853668A (zh) * 2024-06-24 2024-10-29 中山大学 一种靶向SARS-CoV-2的siRNA自组装纳米颗粒及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE443765T1 (de) * 2003-03-21 2009-10-15 Santaris Pharma As Analoga kurzer interferierender rna (sirna)
CN1590545A (zh) * 2003-06-04 2005-03-09 杭州新瑞佳生物医药技术开发有限公司 攻击SARS病毒mRNA分子的小干扰核糖核酸分子（SiRNA）及应用
CN101113158A (zh) * 2006-12-18 2008-01-30 四川大学 干扰SARS病毒RdRp基因功能的siRNA
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
WO2021183887A1 (en) * 2020-03-13 2021-09-16 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for viral genome targeting
TW202204615A (zh) * 2020-03-26 2022-02-01 美商阿尼拉製藥公司 冠狀病毒ｉＲＮＡ組成物及其使用方法
CN111778253B (zh) * 2020-04-03 2022-02-18 苏州吉玛基因股份有限公司 一种小干扰核酸及组合物和应用
CN111748557B (zh) * 2020-04-03 2022-03-11 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
AU2021251249A1 (en) * 2020-04-10 2022-11-10 Aligos Therapeutics, Inc. Short interfering nucleic acid (siNA) molecules and uses thereof for coronavirus diseases
CN111518809A (zh) * 2020-05-12 2020-08-11 杭州勇诚睿生物科技有限公司 干扰新冠病毒COVID-19基因表达的siRNA及其应用
RU2733361C1 (ru) * 2020-07-14 2020-10-01 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией
EP4359528A1 (en) * 2021-06-25 2024-05-01 Alpine Antiviral GmbH Sirna combinations targeting sars-cov-2 and/or host factor transcripts

Also Published As

Publication number Publication date
IL303367A (en) 2023-08-01
CN116964202A (zh) 2023-10-27
EP4256055A4 (en) 2025-07-02
WO2022117085A1 (en) 2022-06-09
AU2021390130A9 (en) 2025-04-03
JP2023553610A (ja) 2023-12-25
US20240026362A1 (en) 2024-01-25
EP4256055A1 (en) 2023-10-11
AU2021390130A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
Chang et al. A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant
KR20230142701A (ko) 중증 급성 호흡기 증후군-관련 코로나바이러스를 표적화하는간섭 rna 및 covid-19 치료를 위한 그의 용도
US11028397B2 (en) 5′-triphosphate oligoribonucleotides
US20140287023A1 (en) 5'-triphosphate oligoribonucleotides
US20140323541A1 (en) Methods And Compositions For Prevention Or Treatment Of RSV Infection Using Modified Duplex RNA Molecules
WO2023098908A1 (en) Modification patterns for small interfering rna molecules with high stability and gene silencing activities
WO2021237297A1 (en) Anti-viral extracellular vesicles, their methods of preparation and uses
CN114729360A (zh) 降低病毒分子水平的方法
CN105555279B (zh) 用于治疗脓毒症的MicroRNA抑制
TW202214296A (zh) 核酸脂質粒子疫苗
WO2023023597A1 (en) Virus-like particle
US20230242918A1 (en) Interferon- inducing oligonucleotide duplexes and methods of use
US20240425853A1 (en) Modified small interfering rna molecules with reduced off-target effects
WO2026067447A1 (en) Small Interfering RNAs Targeting ANT2 and Uses Thereof for Disease Treatment
US20240024405A1 (en) Compositions of caspase inhibitors and methods of use thereof
Reid The role of extracellular vesicle miRNA released in response to influenza A virus.
JP2025534045A (ja) 抗ウイルス核酸および組成物
WO2026096962A1 (en) Methods and compounds for treating, ameliorating and/or preventing fibrotic diseases
WO2024206843A9 (en) Compositions including modified coronavirus vaccines and uses thereof
CN118403065A (zh) 用于肿瘤治疗的化疗药物组合物及其制备方法
CN119709736A (zh) 一种新的siRNA、包含其的组合物及用途
Kim et al. Duox2-derived reactive oxygen species induce pattern recognition receptors’ expression against influenza A virus in nasal mucosa

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230630

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241203

Comment text: Request for Examination of Application